The scope of the multidistrict litigation over Ozempic and related drugs has gotten bigger, but not as big as the plaintiffs would have liked.

The Judicial Panel of Multidistrict Litigation recently opened the MDL to claims involving a drug called Saxenda, but declined to add new types of injuries into the mix.